Theriva Biologics, Inc. 8-K

What Happened
Theriva Biologics (TOVX) announced on July 7, 2026 that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the company to start the VIRAGE2 clinical trial. VIRAGE2 is a Phase IIa, single‑arm, single‑center, open‑label proof‑of‑concept study (EUCT: 2026-525566-21-00) testing increased‑frequency dosing of zabilugene almadenorepvec (VCN‑01) combined with gemcitabine/nab‑paclitaxel in patients with newly‑diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).

Key Details

• Authorization announced via press release filed July 7, 2026.
• VIRAGE2 will evaluate giving at least 3 doses of VCN‑01 every 2 months alongside standard‑of‑care gemcitabine/nab‑paclitaxel.
• The trial builds on the 112‑patient VIRAGE Phase 2b study, where patients receiving 2 doses of VCN‑01 (3 months apart) showed significantly improved overall survival, progression‑free survival, and duration of response versus one dose or chemotherapy alone.
• EMA and FDA previously acknowledged the improved survival signal from the 2‑dose group; VIRAGE2 results will inform dosing for a potential future pivotal Phase 3 trial.

Why It Matters
This filing signals clinical progress for Theriva’s lead oncolytic candidate VCN‑01 and is a step toward defining a repeat‑dosing regimen that could be tested in a pivotal Phase 3 study. For investors, the AEMPS clearance and prior positive signals from the 112‑patient VIRAGE trial are material operational milestones—but VIRAGE2 is an early, small Phase IIa proof‑of‑concept study and does not guarantee regulatory approval or commercial success. The company did not disclose financial impacts or timelines for Phase 3 in the 8‑K.